Literature DB >> 23813282

Associations of baseline characteristics with evolution of eGFR in a referred chronic kidney disease cohort.

R A Hoefield1, P A Kalra, B Lane, D J O'Donoghue, R N Foley, R J Middleton.   

Abstract

BACKGROUND: Currently, most chronic kidney disease (CKD) classifications identify patients at different stages of CKD but do not identify risk of progression or adverse outcome. This analysis aims to describe associations between baseline characteristics and the evolution of estimated glomerular filtration rate (eGFR) and identify threshold values for clinical parameters that maximally discriminate progression to renal replacement therapy (RRT) in a referred cohort of patients with CKD stages 3-5. DESIGN AND METHODS: A longitudinal mixed-effect model was used to determine annualized estimated change in eGFR and classification tree analysis to identify threshold values that maximally discriminate progression to RRT.
RESULTS: A total of 1316 patients were available for analysis with median follow-up of 33 months (interquartile range 20-60). Mixed model analysis suggested that the underlying diagnoses of autosomal dominant polycystic kidney disease and diabetic nephropathy exhibited on average a 2.7 (0.3) and 0.7 (0.3) ml/min/year faster rate of decline in eGFR, respectively, compared to those patients with biopsy-proven glomerulonephritis. In the regression tree analysis, we attempted to identify threshold values for clinical parameters that maximally discriminate progression to RRT. eGFR ≤24 ml/min was the first ranked discriminator, diastolic blood pressure appeared in the second and fourth rounds, eGFR appeared again in the third round together with cholesterol and systolic blood pressure, with basal metabolic index in the fourth.
CONCLUSION: This analysis highlights risk factors for progressive kidney disease and demonstrates the variability in evolution of eGFR across the cohort as well as the importance of underlying renal disease type on the progression of CKD.

Entities:  

Mesh:

Year:  2013        PMID: 23813282     DOI: 10.1093/qjmed/hct115

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  6 in total

1.  The Associations of Blood Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin with Progression from CKD to ESRD.

Authors:  Helen V Alderson; James P Ritchie; Sabrina Pagano; Rachel J Middleton; Menno Pruijm; Nicolas Vuilleumier; Philip A Kalra
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-16       Impact factor: 8.237

2.  Chronic kidney disease progression is mainly associated with non-recovery of acute kidney injury.

Authors:  Eric D'hoore; Nathalie Neirynck; Eva Schepers; Raymond Vanholder; Francis Verbeke; Mira Van Thielen; Wim Van Biesen
Journal:  J Nephrol       Date:  2015-02-21       Impact factor: 3.902

3.  Cognitive impairment in patients with moderate to severe chronic kidney disease: the Salford kidney cohort study.

Authors:  James Tollitt; Aghogho Odudu; Daniela Montaldi; Philip A Kalra
Journal:  Clin Kidney J       Date:  2020-11-03

4.  Impact of prior stroke on major clinical outcome in chronic kidney disease: the Salford kidney cohort study.

Authors:  James Tollitt; Aghogho Odudu; Emma Flanagan; Rajkumar Chinnadurai; Craig Smith; Philip A Kalra
Journal:  BMC Nephrol       Date:  2019-11-27       Impact factor: 2.388

5.  Does previous stroke modify the relationship between inflammatory biomarkers and clinical endpoints in CKD patients?

Authors:  James Tollitt; Stuart M Allan; Rajkumar Chinnadurai; Aghogho Odudu; Margaret Hoadley; Craig Smith; Philip A Kalra
Journal:  BMC Nephrol       Date:  2022-01-18       Impact factor: 2.388

6.  Longitudinal change in c-terminal fibroblast growth factor 23 and outcomes in patients with advanced chronic kidney disease.

Authors:  Helen V Alderson; Rajkumar Chinnadurai; Sara T Ibrahim; Ozgur Asar; James P Ritchie; Rachel Middleton; Anders Larsson; Peter J Diggle; Tobias E Larsson; Philip A Kalra
Journal:  BMC Nephrol       Date:  2021-10-02       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.